Physician profile
Scott Nyboer
NPI 1124017298
$6,626.53
in general payments reported to CMS, 2019-2025
42 companies · $478 in 2025
The $478 reported for 2025 was more than what 78% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,531 · 2020: $1,063 · 2021: $1,085 · 2022: $757 · 2023: $584 · 2024: $1,128 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,190.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,306.99 | 2019-2024 | Proclaim |
| Ipsen Biopharmaceuticals, INC | $750.52 | 2019-2025 | Dysport |
| Collegium Pharmaceutical, INC. | $743.97 | 2019-2024 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $482.90 | 2019-2025 | Relistor |
| Merz Pharmaceuticals, LLC | $388.49 | 2021-2025 | Xeomin |
| Abbvie INC. | $319.30 | 2021-2025 | |
| Microtransponder, INC. | $294.74 | 2024 | |
| Allergan, INC. | $280.28 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $223.61 | 2019-2024 | Ztlido |
| Si-Bone, INC. | $215.26 | 2019-2020 | |
| Saol Therapeutics INC. | $197.62 | 2020 | |
| Pfizer INC. | $179.00 | 2019-2023 | |
| Averitas Pharma INC. | $162.87 | 2023-2025 | Qutenza |
| Ibsa Pharma INC. | $151.45 | 2022-2025 | Tirosint, Licart, Flector |
| Azurity Pharmaceuticals, INC. | $120.99 | 2023-2025 | Horizant, Horizant |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Nyboer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.